Global GalNAc-based Drug Market Growth (Status and Outlook) 2026-2032

March 2026 | 93 pages | ID: G54150C603E6EN
LP Information

US$ 3,660.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global GalNAc-based Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

GalNAc is a ligand for the asialoglycoprotein receptor (ASGPR), which is an endocytic receptor highly specifically expressed on the surface of liver cells, with minimal expression in other cell types. GalNAc-based drugs refer to therapeutics designed using N-acetylgalactosamine (GalNAc) as a key component, aimed at targeting specific cells. These drugs enhance the delivery efficiency and specificity of the therapeutic agents by binding to receptors on the surface of liver cells, thereby improving therapeutic efficacy and reducing side effects.

United States market for GalNAc-based Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for GalNAc-based Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for GalNAc-based Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key GalNAc-based Drug players cover Suzhou Ribo Life Science Co., Ltd, Sirnaomics, Alnylam Pharmaceuticals, Arrowhead, Novo Nordisk (Dicerna), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LPI (LP Information)' newest research report, the “GalNAc-based Drug Industry Forecast” looks at past sales and reviews total world GalNAc-based Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected GalNAc-based Drug sales for 2026 through 2032. With GalNAc-based Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GalNAc-based Drug industry.

This Insight Report provides a comprehensive analysis of the global GalNAc-based Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on GalNAc-based Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global GalNAc-based Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GalNAc-based Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GalNAc-based Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of GalNAc-based Drug market by product type, application, key players and key regions and countries.

Segmentation by Type:
  • siRNA Based
  • ASO Based
Segmentation by Application:
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Neurological Diseases
  • Other
This report also splits the market by region:
  • Americas
    • United States
    • Canada
    • Mexico
    • Brazil
  • APAC
    • China
    • Japan
    • Korea
    • Southeast Asia
    • India
    • Australia
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
  • Middle East & Africa
    • Egypt
    • South Africa
    • Israel
    • Turkey
    • GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
  • Suzhou Ribo Life Science Co., Ltd
  • Sirnaomics
  • Alnylam Pharmaceuticals
  • Arrowhead
  • Novo Nordisk (Dicerna)
  • Ionis
  • Silence Therapeutics
  • Arbutus
  • Novartis
  • Hitgen (Leaderna Therapeutics Ltd.)


The report requires updating with new data and is sent in 48 hours after order is placed.
1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global GalNAc-based Drug Market Size (2021-2032)
  2.1.2 GalNAc-based Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
  2.1.3 World Current & Future Analysis for GalNAc-based Drug by Country/Region (2021, 2025 & 2032)
2.2 GalNAc-based Drug Segment by Type
  2.2.1 siRNA Based
  2.2.2 ASO Based
  2.2.3 GalNAc-based Drug Market Size by Type
    2.2.3.1 GalNAc-based Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
    2.2.3.2 Global GalNAc-based Drug Market Size Market Share by Type (2021-2026)
2.3 GalNAc-based Drug Segment by Application
  2.3.1 Cardiovascular Diseases
  2.3.2 Metabolic Diseases
  2.3.3 Neurological Diseases
  2.3.4 Other
  2.3.5 GalNAc-based Drug Market Size by Application
    2.3.5.1 GalNAc-based Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
    2.3.5.2 Global GalNAc-based Drug Market Size Market Share by Application (2021-2026)

3 GALNAC-BASED DRUG MARKET SIZE BY PLAYER

3.1 GalNAc-based Drug Market Size Market Share by Player
  3.1.1 Global GalNAc-based Drug Revenue by Player (2021-2026)
  3.1.2 Global GalNAc-based Drug Revenue Market Share by Player (2021-2026)
3.2 Global GalNAc-based Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 GALNAC-BASED DRUG BY REGION

4.1 GalNAc-based Drug Market Size by Region (2021-2026)
4.2 Global GalNAc-based Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas GalNAc-based Drug Market Size Growth (2021-2026)
4.4 APAC GalNAc-based Drug Market Size Growth (2021-2026)
4.5 Europe GalNAc-based Drug Market Size Growth (2021-2026)
4.6 Middle East & Africa GalNAc-based Drug Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas GalNAc-based Drug Market Size by Country (2021-2026)
5.2 Americas GalNAc-based Drug Market Size by Type (2021-2026)
5.3 Americas GalNAc-based Drug Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC GalNAc-based Drug Market Size by Region (2021-2026)
6.2 APAC GalNAc-based Drug Market Size by Type (2021-2026)
6.3 APAC GalNAc-based Drug Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe GalNAc-based Drug Market Size by Country (2021-2026)
7.2 Europe GalNAc-based Drug Market Size by Type (2021-2026)
7.3 Europe GalNAc-based Drug Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa GalNAc-based Drug by Region (2021-2026)
8.2 Middle East & Africa GalNAc-based Drug Market Size by Type (2021-2026)
8.3 Middle East & Africa GalNAc-based Drug Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL GALNAC-BASED DRUG MARKET FORECAST

10.1 Global GalNAc-based Drug Forecast by Region (2027-2032)
  10.1.1 Global GalNAc-based Drug Forecast by Region (2027-2032)
  10.1.2 Americas GalNAc-based Drug Forecast
  10.1.3 APAC GalNAc-based Drug Forecast
  10.1.4 Europe GalNAc-based Drug Forecast
  10.1.5 Middle East & Africa GalNAc-based Drug Forecast
10.2 Americas GalNAc-based Drug Forecast by Country (2027-2032)
  10.2.1 United States Market GalNAc-based Drug Forecast
  10.2.2 Canada Market GalNAc-based Drug Forecast
  10.2.3 Mexico Market GalNAc-based Drug Forecast
  10.2.4 Brazil Market GalNAc-based Drug Forecast
10.3 APAC GalNAc-based Drug Forecast by Region (2027-2032)
  10.3.1 China GalNAc-based Drug Market Forecast
  10.3.2 Japan Market GalNAc-based Drug Forecast
  10.3.3 Korea Market GalNAc-based Drug Forecast
  10.3.4 Southeast Asia Market GalNAc-based Drug Forecast
  10.3.5 India Market GalNAc-based Drug Forecast
  10.3.6 Australia Market GalNAc-based Drug Forecast
10.4 Europe GalNAc-based Drug Forecast by Country (2027-2032)
  10.4.1 Germany Market GalNAc-based Drug Forecast
  10.4.2 France Market GalNAc-based Drug Forecast
  10.4.3 UK Market GalNAc-based Drug Forecast
  10.4.4 Italy Market GalNAc-based Drug Forecast
  10.4.5 Russia Market GalNAc-based Drug Forecast
10.5 Middle East & Africa GalNAc-based Drug Forecast by Region (2027-2032)
  10.5.1 Egypt Market GalNAc-based Drug Forecast
  10.5.2 South Africa Market GalNAc-based Drug Forecast
  10.5.3 Israel Market GalNAc-based Drug Forecast
  10.5.4 Turkey Market GalNAc-based Drug Forecast
10.6 Global GalNAc-based Drug Forecast by Type (2027-2032)
10.7 Global GalNAc-based Drug Forecast by Application (2027-2032)
  10.7.1 GCC Countries Market GalNAc-based Drug Forecast

11 KEY PLAYERS ANALYSIS

11.1 Suzhou Ribo Life Science Co., Ltd
  11.1.1 Suzhou Ribo Life Science Co., Ltd Company Information
  11.1.2 Suzhou Ribo Life Science Co., Ltd GalNAc-based Drug Product Offered
  11.1.3 Suzhou Ribo Life Science Co., Ltd GalNAc-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.1.4 Suzhou Ribo Life Science Co., Ltd Main Business Overview
  11.1.5 Suzhou Ribo Life Science Co., Ltd Latest Developments
11.2 Sirnaomics
  11.2.1 Sirnaomics Company Information
  11.2.2 Sirnaomics GalNAc-based Drug Product Offered
  11.2.3 Sirnaomics GalNAc-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.2.4 Sirnaomics Main Business Overview
  11.2.5 Sirnaomics Latest Developments
11.3 Alnylam Pharmaceuticals
  11.3.1 Alnylam Pharmaceuticals Company Information
  11.3.2 Alnylam Pharmaceuticals GalNAc-based Drug Product Offered
  11.3.3 Alnylam Pharmaceuticals GalNAc-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.3.4 Alnylam Pharmaceuticals Main Business Overview
  11.3.5 Alnylam Pharmaceuticals Latest Developments
11.4 Arrowhead
  11.4.1 Arrowhead Company Information
  11.4.2 Arrowhead GalNAc-based Drug Product Offered
  11.4.3 Arrowhead GalNAc-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.4.4 Arrowhead Main Business Overview
  11.4.5 Arrowhead Latest Developments
11.5 Novo Nordisk (Dicerna)
  11.5.1 Novo Nordisk (Dicerna) Company Information
  11.5.2 Novo Nordisk (Dicerna) GalNAc-based Drug Product Offered
  11.5.3 Novo Nordisk (Dicerna) GalNAc-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.5.4 Novo Nordisk (Dicerna) Main Business Overview
  11.5.5 Novo Nordisk (Dicerna) Latest Developments
11.6 Ionis
  11.6.1 Ionis Company Information
  11.6.2 Ionis GalNAc-based Drug Product Offered
  11.6.3 Ionis GalNAc-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.6.4 Ionis Main Business Overview
  11.6.5 Ionis Latest Developments
11.7 Silence Therapeutics
  11.7.1 Silence Therapeutics Company Information
  11.7.2 Silence Therapeutics GalNAc-based Drug Product Offered
  11.7.3 Silence Therapeutics GalNAc-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.7.4 Silence Therapeutics Main Business Overview
  11.7.5 Silence Therapeutics Latest Developments
11.8 Arbutus
  11.8.1 Arbutus Company Information
  11.8.2 Arbutus GalNAc-based Drug Product Offered
  11.8.3 Arbutus GalNAc-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.8.4 Arbutus Main Business Overview
  11.8.5 Arbutus Latest Developments
11.9 Novartis
  11.9.1 Novartis Company Information
  11.9.2 Novartis GalNAc-based Drug Product Offered
  11.9.3 Novartis GalNAc-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.9.4 Novartis Main Business Overview
  11.9.5 Novartis Latest Developments
11.10 Hitgen (Leaderna Therapeutics Ltd.)
  11.10.1 Hitgen (Leaderna Therapeutics Ltd.) Company Information
  11.10.2 Hitgen (Leaderna Therapeutics Ltd.) GalNAc-based Drug Product Offered
  11.10.3 Hitgen (Leaderna Therapeutics Ltd.) GalNAc-based Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.10.4 Hitgen (Leaderna Therapeutics Ltd.) Main Business Overview
  11.10.5 Hitgen (Leaderna Therapeutics Ltd.) Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

LIST OF TABLES

Table 1. GalNAc-based Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. GalNAc-based Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of siRNA Based
Table 4. Major Players of ASO Based
Table 5. GalNAc-based Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global GalNAc-based Drug Market Size by Type (2021-2026) & ($ millions)
Table 7. Global GalNAc-based Drug Market Size Market Share by Type (2021-2026)
Table 8. GalNAc-based Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global GalNAc-based Drug Market Size by Application (2021-2026) & ($ millions)
Table 10. Global GalNAc-based Drug Market Size Market Share by Application (2021-2026)
Table 11. Global GalNAc-based Drug Revenue by Player (2021-2026) & ($ millions)
Table 12. Global GalNAc-based Drug Revenue Market Share by Player (2021-2026)
Table 13. GalNAc-based Drug Key Players Head office and Products Offered
Table 14. GalNAc-based Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global GalNAc-based Drug Market Size by Region (2021-2026) & ($ millions)
Table 18. Global GalNAc-based Drug Market Size Market Share by Region (2021-2026)
Table 19. Global GalNAc-based Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global GalNAc-based Drug Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas GalNAc-based Drug Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas GalNAc-based Drug Market Size Market Share by Country (2021-2026)
Table 23. Americas GalNAc-based Drug Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas GalNAc-based Drug Market Size Market Share by Type (2021-2026)
Table 25. Americas GalNAc-based Drug Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas GalNAc-based Drug Market Size Market Share by Application (2021-2026)
Table 27. APAC GalNAc-based Drug Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC GalNAc-based Drug Market Size Market Share by Region (2021-2026)
Table 29. APAC GalNAc-based Drug Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC GalNAc-based Drug Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe GalNAc-based Drug Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe GalNAc-based Drug Market Size Market Share by Country (2021-2026)
Table 33. Europe GalNAc-based Drug Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe GalNAc-based Drug Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa GalNAc-based Drug Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa GalNAc-based Drug Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa GalNAc-based Drug Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of GalNAc-based Drug
Table 39. Key Market Challenges & Risks of GalNAc-based Drug
Table 40. Key Industry Trends of GalNAc-based Drug
Table 41. Global GalNAc-based Drug Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global GalNAc-based Drug Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global GalNAc-based Drug Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global GalNAc-based Drug Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Suzhou Ribo Life Science Co., Ltd Details, Company Type, GalNAc-based Drug Area Served and Its Competitors
Table 46. Suzhou Ribo Life Science Co., Ltd GalNAc-based Drug Product Offered
Table 47. Suzhou Ribo Life Science Co., Ltd GalNAc-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Suzhou Ribo Life Science Co., Ltd Main Business
Table 49. Suzhou Ribo Life Science Co., Ltd Latest Developments
Table 50. Sirnaomics Details, Company Type, GalNAc-based Drug Area Served and Its Competitors
Table 51. Sirnaomics GalNAc-based Drug Product Offered
Table 52. Sirnaomics GalNAc-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Sirnaomics Main Business
Table 54. Sirnaomics Latest Developments
Table 55. Alnylam Pharmaceuticals Details, Company Type, GalNAc-based Drug Area Served and Its Competitors
Table 56. Alnylam Pharmaceuticals GalNAc-based Drug Product Offered
Table 57. Alnylam Pharmaceuticals GalNAc-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Alnylam Pharmaceuticals Main Business
Table 59. Alnylam Pharmaceuticals Latest Developments
Table 60. Arrowhead Details, Company Type, GalNAc-based Drug Area Served and Its Competitors
Table 61. Arrowhead GalNAc-based Drug Product Offered
Table 62. Arrowhead GalNAc-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Arrowhead Main Business
Table 64. Arrowhead Latest Developments
Table 65. Novo Nordisk (Dicerna) Details, Company Type, GalNAc-based Drug Area Served and Its Competitors
Table 66. Novo Nordisk (Dicerna) GalNAc-based Drug Product Offered
Table 67. Novo Nordisk (Dicerna) GalNAc-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Novo Nordisk (Dicerna) Main Business
Table 69. Novo Nordisk (Dicerna) Latest Developments
Table 70. Ionis Details, Company Type, GalNAc-based Drug Area Served and Its Competitors
Table 71. Ionis GalNAc-based Drug Product Offered
Table 72. Ionis GalNAc-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Ionis Main Business
Table 74. Ionis Latest Developments
Table 75. Silence Therapeutics Details, Company Type, GalNAc-based Drug Area Served and Its Competitors
Table 76. Silence Therapeutics GalNAc-based Drug Product Offered
Table 77. Silence Therapeutics GalNAc-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Silence Therapeutics Main Business
Table 79. Silence Therapeutics Latest Developments
Table 80. Arbutus Details, Company Type, GalNAc-based Drug Area Served and Its Competitors
Table 81. Arbutus GalNAc-based Drug Product Offered
Table 82. Arbutus GalNAc-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Arbutus Main Business
Table 84. Arbutus Latest Developments
Table 85. Novartis Details, Company Type, GalNAc-based Drug Area Served and Its Competitors
Table 86. Novartis GalNAc-based Drug Product Offered
Table 87. Novartis GalNAc-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Novartis Main Business
Table 89. Novartis Latest Developments
Table 90. Hitgen (Leaderna Therapeutics Ltd.) Details, Company Type, GalNAc-based Drug Area Served and Its Competitors
Table 91. Hitgen (Leaderna Therapeutics Ltd.) GalNAc-based Drug Product Offered
Table 92. Hitgen (Leaderna Therapeutics Ltd.) GalNAc-based Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Hitgen (Leaderna Therapeutics Ltd.) Main Business
Table 94. Hitgen (Leaderna Therapeutics Ltd.) Latest Developments

LIST OF FIGURES

Figure 1. GalNAc-based Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global GalNAc-based Drug Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. GalNAc-based Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. GalNAc-based Drug Sales Market Share by Country/Region (2025)
Figure 8. GalNAc-based Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global GalNAc-based Drug Market Size Market Share by Type in 2025
Figure 10. GalNAc-based Drug in Cardiovascular Diseases
Figure 11. Global GalNAc-based Drug Market: Cardiovascular Diseases (2021-2026) & ($ millions)
Figure 12. GalNAc-based Drug in Metabolic Diseases
Figure 13. Global GalNAc-based Drug Market: Metabolic Diseases (2021-2026) & ($ millions)
Figure 14. GalNAc-based Drug in Neurological Diseases
Figure 15. Global GalNAc-based Drug Market: Neurological Diseases (2021-2026) & ($ millions)
Figure 16. GalNAc-based Drug in Other
Figure 17. Global GalNAc-based Drug Market: Other (2021-2026) & ($ millions)
Figure 18. Global GalNAc-based Drug Market Size Market Share by Application in 2025
Figure 19. Global GalNAc-based Drug Revenue Market Share by Player in 2025
Figure 20. Global GalNAc-based Drug Market Size Market Share by Region (2021-2026)
Figure 21. Americas GalNAc-based Drug Market Size 2021-2026 ($ millions)
Figure 22. APAC GalNAc-based Drug Market Size 2021-2026 ($ millions)
Figure 23. Europe GalNAc-based Drug Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa GalNAc-based Drug Market Size 2021-2026 ($ millions)
Figure 25. Americas GalNAc-based Drug Value Market Share by Country in 2025
Figure 26. United States GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC GalNAc-based Drug Market Size Market Share by Region in 2025
Figure 31. APAC GalNAc-based Drug Market Size Market Share by Type (2021-2026)
Figure 32. APAC GalNAc-based Drug Market Size Market Share by Application (2021-2026)
Figure 33. China GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 37. India GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe GalNAc-based Drug Market Size Market Share by Country in 2025
Figure 40. Europe GalNAc-based Drug Market Size Market Share by Type (2021-2026)
Figure 41. Europe GalNAc-based Drug Market Size Market Share by Application (2021-2026)
Figure 42. Germany GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 43. France GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 44. UK GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa GalNAc-based Drug Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa GalNAc-based Drug Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa GalNAc-based Drug Market Size Market Share by Application (2021-2026)
Figure 50. Egypt GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries GalNAc-based Drug Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 56. APAC GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 57. Europe GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 59. United States GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 60. Canada GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 61. Mexico GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 62. Brazil GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 63. China GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 64. Japan GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 65. Korea GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 67. India GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 68. Australia GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 69. Germany GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 70. France GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 71. UK GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 72. Italy GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 73. Russia GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 74. Egypt GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 75. South Africa GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 76. Israel GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 77. Turkey GalNAc-based Drug Market Size 2027-2032 ($ millions)
Figure 78. Global GalNAc-based Drug Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global GalNAc-based Drug Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries GalNAc-based Drug Market Size 2027-2032 ($ millions)


More Publications